Senetek PLC's Invicorp Cited as Highly Safe and Effective Treatment For Erectile Dysfunction in Diabetic Men With Severe ED

Apr 23, 2001, 01:00 ET from Senetek PLC

    NAPA, Calif., April 23 /PRNewswire Interactive News Release/ -- Senetek
 PLC (Nasdaq:   SNTKY), http://www.senetekplc.com, which develops products in two
 key markets, anti-aging and sexual dysfunction, today announced that a new
 study conducted in England strongly supports "the safety and efficacy of
 Invicorp," its treatment for erectile dysfunction, in men with diabetes.  A
 total of 23 patients were studied in the double blind, placebo controlled
 trial.  Results demonstrated a response rate suitable for sexual intercourse
 of 77 percent for those using Invicorp(TM) compared to 19 percent for placebo,
 a highly statistically significant result.  It is noteworthy that the study
 included only men with severe to complete ED.  Mild and transient facial
 flushing was the only side effect noted.
     "Many diabetic men develop ED and as a group are often difficult to treat,
 being unresponsive to existing pharmacotherapy, including oral medication,"
 Dr. Phillip Kell said.  "This study, which included only men with severe to
 complete erectile failure, strongly supports the efficacy and safety of
 Invicorp."
     The investigators, Dr. C.J. Speirs, Epsom General Hospital, Dr. S. Beer,
 Diabetes Centre - Scunthrope General Hospital, and Dr. Phillip Kell, Archway
 Sexual Health Clinic, are Diabetologists and "Consultant Physicians practicing
 in the United Kingdom."
     Decision Resources, Inc., a world leader in research for the health care
 industry, in a report on ED, found that experts believe Invicorp, which is a
 combination of vasoactive intestinal polypeptide (VIP) and phentolamine
 mesylate (PMS), might be particularly appropriate for diabetic men because a
 deficiency of VIP may be involved in diabetic neuropathy.  Diabetes is one of
 the leading risk factors for ED, with more than 50 percent of diabetics
 experiencing some form of ED within five years of the onset of the disease.
 Diabetes is believed to interfere with numerous critical erectile mechanisms.
     Senetek PLC, headquartered in Napa, Ca., http://www.senetekplc.com, is a
 science-driven biopharmaceutical company engaged in the development of
 products for anti-aging and sexual dysfunction.
 
            Visit SENETEK PLC's Website at http://www.senetekplc.com
 
     This press release and Website may contain certain forward-looking
 statements.  Actual events or results may differ from the Company's
 expectations as a result of a number of factors, including those set forth in
 Senetek's Annual Report, its Form 10K and subsequent regulatory filings.
 There can be no assurance that any product in Senetek's product pipeline will
 be successfully developed or manufactured, or that final results of human
 pilot studies or clinical studies will be supportive of regulatory approvals
 required to market products.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X65533105
 
 

SOURCE Senetek PLC
    NAPA, Calif., April 23 /PRNewswire Interactive News Release/ -- Senetek
 PLC (Nasdaq:   SNTKY), http://www.senetekplc.com, which develops products in two
 key markets, anti-aging and sexual dysfunction, today announced that a new
 study conducted in England strongly supports "the safety and efficacy of
 Invicorp," its treatment for erectile dysfunction, in men with diabetes.  A
 total of 23 patients were studied in the double blind, placebo controlled
 trial.  Results demonstrated a response rate suitable for sexual intercourse
 of 77 percent for those using Invicorp(TM) compared to 19 percent for placebo,
 a highly statistically significant result.  It is noteworthy that the study
 included only men with severe to complete ED.  Mild and transient facial
 flushing was the only side effect noted.
     "Many diabetic men develop ED and as a group are often difficult to treat,
 being unresponsive to existing pharmacotherapy, including oral medication,"
 Dr. Phillip Kell said.  "This study, which included only men with severe to
 complete erectile failure, strongly supports the efficacy and safety of
 Invicorp."
     The investigators, Dr. C.J. Speirs, Epsom General Hospital, Dr. S. Beer,
 Diabetes Centre - Scunthrope General Hospital, and Dr. Phillip Kell, Archway
 Sexual Health Clinic, are Diabetologists and "Consultant Physicians practicing
 in the United Kingdom."
     Decision Resources, Inc., a world leader in research for the health care
 industry, in a report on ED, found that experts believe Invicorp, which is a
 combination of vasoactive intestinal polypeptide (VIP) and phentolamine
 mesylate (PMS), might be particularly appropriate for diabetic men because a
 deficiency of VIP may be involved in diabetic neuropathy.  Diabetes is one of
 the leading risk factors for ED, with more than 50 percent of diabetics
 experiencing some form of ED within five years of the onset of the disease.
 Diabetes is believed to interfere with numerous critical erectile mechanisms.
     Senetek PLC, headquartered in Napa, Ca., http://www.senetekplc.com, is a
 science-driven biopharmaceutical company engaged in the development of
 products for anti-aging and sexual dysfunction.
 
            Visit SENETEK PLC's Website at http://www.senetekplc.com
 
     This press release and Website may contain certain forward-looking
 statements.  Actual events or results may differ from the Company's
 expectations as a result of a number of factors, including those set forth in
 Senetek's Annual Report, its Form 10K and subsequent regulatory filings.
 There can be no assurance that any product in Senetek's product pipeline will
 be successfully developed or manufactured, or that final results of human
 pilot studies or clinical studies will be supportive of regulatory approvals
 required to market products.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X65533105
 
 SOURCE  Senetek PLC

RELATED LINKS

http://www.senetekplc.com